Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

XTL Biopharmaceuticals in-licenses hCDR1 for lupus

Jan. 13, 2014

Adheron Therapeutics reports phase I data for SDP-051

Jan. 10, 2014

Ribomic presents new aptamers for rheumatoid arthritis and other disorders

Jan. 9, 2014

Horizon-labeled Vimovo now available in the U.S.

Jan. 3, 2014

New mitochondrial F1F0-ATPase inhibitors designed by Lycera Corp.

Jan. 2, 2014

Lycera Corp. discloses new inhibitors of F1F0-ATPase

Dec. 31, 2013

Can-Fite BioPharma reports topline results from phase IIb study of CF-101

Dec. 30, 2013

Phase IIa study of Santarus' SAN-300 in rheumatoid arthritis begins

Dec. 30, 2013

CHMP gives positive opinion on subcutaneous tocilizumab

Dec. 27, 2013

Auxilium Pharmaceuticals submits supplemental BLA to the FDA for Xiaflex

Dec. 24, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...